3-Drugs Chemotherapy Regimen for G3 PanNENs with Ki67 below 55%: Single Institution Experience Abstract #1396

Introduction: To date no standard regimen of chemotherapy (CTH) is universally approved for advanced pancreatic neuroendocrine neoplasms (PanNENs) with Ki67<55% and no predictive selection criteria is available.
Aim(s): To retrospectively assess the outcomes obtained with CHT in PanNENs with Ki67<55%.
Materials and methods: We retrospectively reviewed data from unresectable PanNENs patients (P) who received CHT during 2011-2015. Ki67% > 55% or mixed hystological type were excluded. P underwent CHT with STZ/5FU (2C) or DTIC-5FU-CDDP (3C) and were separately analyzed.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Medical treatment - Chemotherapy
Presenting Author: MD Elisabetta Grego

To read results and conclusion, please login ...

Further abstracts you may be interested in

No result